Research, Charts & Company Announcements
Research Tree provides access to ongoing research coverage, media content and regulatory news on MorphoSys AG. We currently have 12 research reports from 3 professional analysts.
Date | Source | Announcement |
---|---|---|
13Dec16 06:30 | GNW | MorphoSys Starts Phase 2 Trial of MOR208 in Combination with Idelalisib in Patients with Relapsed or Refractory CLL or SLL Previously Treated with a BTK Inhibitor |
06Dec16 06:30 | GNW | MorphoSys Presents Updated Clinical Results for Anti-CD38 Antibody MOR202 at ASH 2016 |
06Dec16 06:30 | GNW | MorphoSys Presents Updated Clinical Data for Blood Cancer Candidate MOR208 in NHL and CLL at ASH 2016 Conference: |
28Nov16 11:07 | GNW | MorphoSys Announces That Its Licensee Janssen Has Submitted a Marketing Authorisation Application For Guselkumab in Europe |
17Nov16 13:46 | GNW | MorphoSys Announces That Its Licensee Janssen Has Submitted Biologics License Application For Guselkumab |
15Nov16 22:35 | GNW | MorphoSys Raises EUR 115 million in Private Placement |
15Nov16 22:34 | GNW | Ad hoc: MorphoSys Raises EUR 115 million in Private Placement |
Share: